Company: LNAI
Filing Date: 2025-03-06
Form Type: 425
Source: 0001731122-25-000356
Chunk: 4

Company: Lunai Bioworks Inc.
Filing Date: 2025-03-06
Form: 425
Chunk 4
---
 retain key personnel, and any
changes in general economic and/or industry-specific conditions.

In addition to the factors set forth above, other factors
that may affect Renovaro’s plans, results or stock price are set forth in its most recent Annual Report on Form 10-K and in its
subsequently filed reports on Forms 10-Q and 8-K.

Many of these factors are beyond Renovaro’s control.
Renovaro cautions investors that any forward-looking statements made by it are not guarantees of future performance. Renovaro disclaims
any obligation to update any such factors or to announce publicly the results of any revisions to any of the forward-looking statements
to reflect future events or developments, except as required by applicable law.

| Item 9.01 | Financial Statements and Exhibits. |

(d) Exhibits

| Exhibit No 
 10.1       |     | Description                                                                                               
 Extension Amendment, dated February 28, 2025, by and between Renovaro, Inc. and Predictive Oncology, Inc. |
|:-----------|:----|:----------------------------------------------------------------------------------------------------------|
| 104        |     | Cover Page Interactive Data File (embedded within the Inline XBRL document)                               |

<div align='center'>SIGNATURE</div>

Pursuant to the requirements of the Securities Exchange
Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

| Date: March 6, 2025 | RENOVARO, INC. 
 By:            | /s/ Nathen Fuentes                      |
|:--------------------|:---------------|:----------------------------------------|
|                     |                | Nathen Fuentes, Chief Financial Officer |